cdmo.directory
← Compare landing

Merck KGaA vs SK pharmteco

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryMerck KGaASK pharmteco
SummaryRecent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea.SK pharmteco is a CDMO offering comprehensive drug development and manufacturing services.
ServicesData not yet provided.
  • Small Molecule Development & Manufacturing
  • API Synthesis & Manufacturing
  • HPAPI Manufacturing (High-Potency)
  • Flow Chemistry & Continuous Manufacturing
  • ADC Payload & Linker Synthesis
  • Viral Vector Manufacturing
  • AAV Manufacturing
  • Lentiviral Vector Manufacturing
  • Peptide Manufacturing
  • Process Development
  • Technology Transfer
  • CMC Analytical Development
  • Quality Control Testing
  • CMC Regulatory Submission Support
ModalitiesData not yet provided.
  • Small Molecule
  • Antibody-Drug Conjugate (ADC)
  • Gene Therapy
  • Peptide
  • AAV / Viral Vector Platform
Development capabilitiesData not yet provided.
  • Analytical method development
  • Formulation development
Manufacturing capabilitiesData not yet provided.
  • Drug Substance (DS)
  • Drug Product (DP)
  • HPAPI
  • Flow Chemistry
Locations
  • Daejeon Bioprocessing Center, Daejeon, South Korea
  • Rancho Cordova, Rancho Cordova, California, USA
  • Texas, Texas, USA
  • King of Prussia, King of Prussia, Pennsylvania, USA
  • Dublin, Swords, Dublin, Ireland
  • Corbeil-Essonnes, Corbeil-Essonnes, Île-de-France, France
  • Daejeon, Daejeon, South Korea
  • Sejong, Sejong, South Korea
CertificationsData not yet provided.Data not yet provided.

Find similar companies

Merck KGaA alternatives · SK pharmteco alternatives

Markdown mirror: /compare/merck-kgaa/skpharmteco.md